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New Developments in Hyperbaric Oxygen Therapy 
Abstract 
Hyperbaric Oxygen Therapy, or HBOT, is a form of treatment based on the inhalation of 100% pure oxygen 
while subjected to closed chamber or room at pressures greater than sea level (1 atmosphere, ATA) 
(Howell et al., 2018; Kocaman, 2020). HBOT is administered through either a mono-place chamber or a 
multi-place chamber. Mono-place chambers are pressurized with oxygen and are equipped to handle a 
single person at a time. Multi-place chambers, on the other hand, can accommodate up to 20 people at a 
time, including medical personnel and intubated patients. These chambers are pressurized with air, and 
pure oxygen is administered via facemask, hood tent, or endotracheal tube (Gill & Bell, 2004; Howell et al., 
2018). Oxygen is primarily used by the body in the formation of ATP, the molecule responsible for fueling 
cellular processes. When body tissues are injured or damaged, the energetic demand increases, and 
consequently more oxygen is needed (Kahle & Cooper, 2020). HBOT increases the body’s arterial and 
tissue oxygen tension, augmenting the amount of oxygen that the blood plasma can carry. This can 
create a number of beneficial biochemical, cellular, and physiologic effects (Tibbles & Edelsberg, 1996). 
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Hyperbaric Oxygen Therapy, or HBOT, is a form of treatment based on the inhalation of 
100% pure oxygen while subjected to closed chamber or room at pressures greater than sea level 
(1 atmosphere, ATA) (Howell et al., 2018; Kocaman, 2020). HBOT is administered through 
either a mono-place chamber or a multi-place chamber. Mono-place chambers are pressurized 
with oxygen and are equipped to handle a single person at a time. Multi-place chambers, on the 
other hand, can accommodate up to 20 people at a time, including medical personnel and 
intubated patients. These chambers are pressurized with air, and pure oxygen is administered via 
facemask, hood tent, or endotracheal tube (Gill & Bell, 2004; Howell et al., 2018). Oxygen is 
primarily used by the body in the formation of ATP, the molecule responsible for fueling cellular 
processes. When body tissues are injured or damaged, the energetic demand increases, and 
consequently more oxygen is needed (Kahle & Cooper, 2020). HBOT increases the body’s 
arterial and tissue oxygen tension, augmenting the amount of oxygen that the blood plasma can 
carry. This can create a number of beneficial biochemical, cellular, and physiologic effects 
(Tibbles & Edelsberg, 1996). 
The first documented use of Hyperbaric Therapy occurred in 1662, even before oxygen 
was discovered, when a British physician created an airtight container, called a ‘domicilium’, in 
which the pressure could be altered using bellows and valves (Carden, 2020; Gill & Bell, 2004). 
It was not until 1872 that this process was scientifically explained by Paul Bert, who wrote about 
the physiological effects of oxygen under increased pressure which granted him the title of ‘the 
Father of Hyperbaric Medicine’ (Carden, 2020; Gill & Bell, 2004). After this point, physicians 
and scientists began to explore the use of HBOT to treat a variety of diseases and conditions, 
including diabetes, arthritis, syphilis, and carbon monoxide intoxication, despite the lack of 
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empirical evidence supporting its efficacy (Carden, 2020; Kocaman, 2020). Since then, however, 
extensive research on the use of hyperbaric oxygen has been performed, especially by the United 
States Naval Academy in the context of deep-sea diving and the treatment of decompression 
sickness (Behnke, 1945; Carden, 2020) 
PHYSIOLOGY 
 As noted previously, Hyperbaric Oxygen Therapy uses pure oxygen at high pressure in a 
closed environment to treat numerous pathologies. The primary effect of HBOT is hyperoxia 
while the secondary effects are the result of controlled oxidative stress (Choudhury, 2018). These 
phenomena, in principle, are governed by the Gas Laws (Choudhury, 2018; Kocaman, 2020; 
Leach, 1998; Tibbles & Edelsberg, 1996). 
Dalton’s law states that in a mixture of gases, the sum of the partial pressures of the gases 
will equal the total pressure in the system (Cosgrove & Bryson, 2001; Choudhury, 2018; Gill & 
Bell, 2004). 
Henry’s law states that at a constant temperature, the amount of gas that dissolves in a 
given type and volume of liquid is directly proportional to the partial pressure of that gas in 
equilibrium with that liquid (Cosgrove & Bryson, 2001; Choudhury, 2018; Kocaman, 2020). 
Primary Effects 
Oxygen is transferred to cells via plasma, and the initial diffusion of oxygen into the 
plasma can be understood by the application of Dalton’s Law and Henry’s Law (Cosgrove & 
Bryson, 2001; Choudhury, 2018). Air is composed of approximately 21% oxygen and 79% 
nitrogen (Cosgrove & Bryson, 2001). The consequence of Dalton’s Law is that the partial 
pressure of oxygen in the air is solely based on the percentage of oxygen in the atmosphere and 
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the ambient pressure, which may vary based on altitude and other factors (Choudhury, 2018). 
The partial pressure of oxygen (PaO2) in air at sea level (1 ATA = 760 mmHg) is calculated as 
160 mmHg (Cosgrove & Bryson, 2001). Air in the trachea, however, has a similar partial 
pressure to humidified water (47 mmHg); thus, a more appropriate calculation of inspired 
oxygen at sea level would result in a PaO2 of 150 mmHg. Deoxygenated blood entering the lung 
contains a PaO2 of 40 mmHg. After the diffusion of oxygen from the environment to the lungs, 
the final PaO2 in the blood is 100 mmHg (Choudhury, 2018) and 50 mm Hg in the tissues (Gill 
& Bell, 2004). These PaO2 values are dependent on the gradient between the partial pressure 
present in the alveoli and in the deoxygenated blood (Choudhury, 2018). Therefore, a larger 
difference in these two partial pressures produces greater oxygen diffusion from the alveoli into 
the plasma (Tibbles & Edelsburg, 1996). Henry’s law can be used to determine how much 
oxygen is dissolved in plasma. According to calculations using the O2 solubility coefficient, the 
PaO2 in the blood and tissues at normobaric conditions allows for the maximum delivery of 0.3 
mL oxygen per deciliter of blood (Choudhury, 2018; Tibbles & Edelsburg, 1996) but tissues 
require 5-6 mL O2/dL of blood for homeostasis (Choudhury, 2018). Hemoglobin makes up for 
this difference; in fact, most oxygen carried in the blood is bound to hemoglobin (Gill & Bell, 
2004). 
Hyperbaric Oxygen Therapy takes advantage of both Dalton’s law and Henry’s law to 
increase the alveoli-plasma gradient and solubility of oxygen, respectively. To portray this 
numerically, administering 100% oxygen at 3 ATA increases arterial oxygen tension to 2000 
mmHg and tissue oxygen tension to 500 mmHg, allowing the delivery of 6 mL O2/dL (Gill & 
Bell, 2004). Evidently, following HBOT, the dissolved oxygen carried by the plasma is sufficient 
in maintaining homeostatic conditions without a contribution from hemoglobin (Kocaman, 
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2020). As a result, this oxygen can be carried to tissues even with impaired hemoglobin oxygen 
carriage, such as the case in carbon monoxide poisoning and severe anemia. The other advantage 
of using plasma to distribute oxygen rather than hemoglobin is that with plasma, oxygen can 
reach physically obstructed areas (like clots or occlusions) where red blood cells cannot pass 
(Gill & Bell, 2004). 
Secondary Effects 
 The primary effects of HBOT include correcting the hypoxic state by increasing oxygen 
delivery and tension, but it is important to note that the application of HBOT to treat many 
diseases derives from the secondary effects of hyperoxia at pressure (Choudhury, 2018). The 
secondary, or indirect effects of HBOT, include the increase of the generation of oxygen free 
radicals (ROS), the increase in the body’s healing ability & immunity, vasoconstriction, 
angiogenesis, and the decrease in edema (Sureda et al., 2016; Choudhury, 2018; Kahle & 
Cooper, 2020). These effects will be specifically addressed in relation to their clinical 
application(s) in the following pages. 
THERAPEUTIC APPLICATIONS 
Decompression Illness 
 Decompression illness denotes two pathological syndromes—arterial gas embolism 
(AGE) and decompression sickness (DCS)—that are caused by intravascular bubbles formed as a 
result of a reduction in environmental pressure (Vann et al., 2011). Another gas law, Boyle’s 
law, explains the root of these syndromes as well as the beneficial effects of HBOT for treating 
them. Boyle’s law states that at a constant temperature, the volume of gas in an enclosed space is 
proportional to the pressure exerted on it (Tibbles & Edelsburg, 1996; Gill & Bell, 2004).  
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Arterial gas embolism and decompression sickness have historically been associated with 
recreational diving (Diaconu et al., 2018). As a diver descends in the water column, the 
increasing barometric pressure has two major effects. The first is mechanical: in the context of 
Boyle’s law, the volume of any gas-containing space in the body is reduced. Thus, if one starts 
off with X volume in the lungs on the surface and breaths to a depth without breathing any 
additional gas, X will be halved (X/2). If one breathes from a gas source while at that depth, the 
lungs will return to X. Should the diver then swim back to the surface, the X will double (2X). 
This enlarging volume of gas is typically exhaled, but in cases that it is not (such as breath 
holding or rapid ascent) then mechanical forces can result in disruption of lung tissue, causing 
pulmonary overinflation (Vann et al., 2011; Hamm, 2019; Neuman, 2002). An example of a 
pulmonary overinflation syndrome is AGE. In this condition, expanding gas ruptures alveoli 
capillaries (pulmonary barotrauma) and is forced into the pulmonary vasculature and arterial 
circulation (Neuman, 2002; Vann et al., 2011). Aside from diving injury, arterial gas embolism 
may be caused by a number of iatrogenic reasons including mechanical ventilation, central line 
placement, and hemodialysis (Kocaman, 2020; Gill & Bell, 2004). In non-fatal cases, air bubbles 
partially block circulation. The clinical picture is aggravated, however, when platelets, 
leukocytes, fibrinogen, and thrombin adhere to the bubble, initiating the thrombotic process and 
causing deterioration of the vessel (Kocaman, 2020). These situations are manifested in the 
clinical effects, which range from muscle and joint pain to more life-threatening problems like 
Acute Respiratory Distress Syndrome (ARDS), brain edema, lack of brain metabolism, and 
sudden death (Kocaman, 2020; Gill & Bell, 2004; Vann et al., 2011). 
The second category of physiological problems associated with decompression is based 
on Dalton’s law and Henry’s law (see page 3) (Choudhury, 2018). As a diver descends, the 
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partial pressures of the gases they breathe is increased, which is reflected in alveolar gas and 
arterial blood. Eventually, increasing amounts of gas are driven into solution in the body tissues. 
When using air as a breathing medium, nitrogen gas is driven into solution. Depending on the 
amount of gas driven into solution, a varying number of bubbles will form during decompression 
due to the reduction in ambient pressure (Vann et al., 2011; Neuman, 2002). This gas phase 
causes the signs and symptoms that are collectively referred to as DCS. Like AGE, these run on 
a spectrum from rash to extreme joint pain (‘the bends’) paralysis, seizures, and even death as a 
result of the blocking of lymphatics, veins, and arteries by the gas bubbles (Tibbles & Edelsburg, 
1996; Vann et al., 2011; Hamm, 2019; Neuman, 2020). 
HBOT is widely accepted as the only treatment for decompression sickness and arterial 
gas embolism (Vann et al., 2011; Kocaman, 2020). During pressurization, also known as the 
compression phase of HBOT, a contraction occurs in the gas-containing cavities of the body (as 
predicted by Boyle’s law), which helps to decrease the air bubbles and relieve the pressure 
present in the tissue and intravascular area (Kocaman, 2020; Tibbles & Edelsburg, 1996; Gill & 
Bell, 2004). Additionally, hyperbaric oxygen hastens the dissolution of the inert gas bubble by 
replacing the inert gas with oxygen, which is then rapidly metabolized by the tissues. It can also 
serve to oxygenate compromised tissues and ameliorate the inflammatory responses that 
contribute to tissue injury (Vann et al., 2011). In one case, administering 100% oxygen at 2.8 
ATA reduced bubble volume by almost two thirds (Tibbles & Edelsburg, 1996). 
Carbon Monoxide Poisoning 
Carbon monoxide poisoning is the most common cause of death by poisoning in the 
United States (Tibbles & Edelsburg, 1996). Upon inhalation, CO binds to hemoglobin due to its 
high affinity as a gas, creating reduced arterial oxygenation and hypoxia within the cell at the 
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mitochondrial level (Kocaman, 2020; Gill & Bell, 2004). This creates a number of symptoms 
from dizziness and headache to seizures, dysrhythmias, and coma. CO also binds to cytochrome-
c oxidase and myoglobin, causing delayed neurological symptoms including cognitive deficits, 
cortical blindness, and psychosis (Gill & Bell, 2004). The primary effects of HBOT can be 
observed in its use to effectively treat CO poisoning (Choudhury, 2018). HBOT speeds up the 
separation of CO gas from hemoglobin, shortening the time it takes to be excreted from the body 
and correcting intracellular hypoxia (Kocaman, 2020). While breathing room air, this process 
takes 300 minutes, but with HBOT the time is shortened to 32 minutes. Additionally, HBOT 
restores cytochrome-c oxidase and myoglobin, which helps to prevent the delayed neurologic 
sequelae (Latham, 2020). Studies describe mixed conclusions about the use of HBOT for CO 
poisoning. In one severe case of CO poisoning, HBOT preserved cognitive function but lesions 
in peripheral nerves persisted, which suggests partial resolution of neurological dysfunction via 
HBOT (Sinkovi et al., 2006). Another recent study suggested performing HBOT within 22 hours 
after poisoning to fully prevent delayed neurological sequelae (Liao et al., 2018). More studies 
are needed to confirm the optimal timing for commencing HBOT in patients with CO poisoning. 
Chronic Wounds 
Normal wound healing is a positive feedback system that proceeds through stages of 
hemostasis, removal of infectious agents, resolution of the inflammatory response, 
reestablishment of a connective tissue matrix, angiogenesis, and resurfacing (Tal et al., 2017). 
Chronic wounds are those which do not proceed completely through this process due to an 
intrinsic or extrinsic problem occurring in one or more of the healing phases (Kocaman, 2020; 
Latham, 2020). These include diabetic wounds, venous stasis ulcers, arterial ulcers, and pressure 
ulcers (Latham, 2020). Infection and ischemia are the most common causes of wound healing 
Scheetz 9 
 
delay with hypoxia as their defining feature (Kocaman, 2020). The infection causes an 
exaggerated response in the inflammatory phase of wound healing, resulting in rapid depletion of 
oxygen in the tissue and insufficient blood flow as a result of edema. Ischemia occurs when the 
tissue lacks oxygen, causing a delay in cellular activity and consequential interruption the 
healing process (Kocaman, 2020; Gill & Bell, 2004). 
Hyperbaric Oxygen Therapy helps to restore the healing process by increasing the 
amount of oxygen in the blood and providing a favorable gradient for the diffusion of oxygen 
into the affected tissues (Kocaman, 2020; Sureda et al., 2016). Adequate oxygen is essential to 
healing since fibroblast proliferation, collagen synthesis, angiogenesis, and infection resistance 
are oxygen-dependent processes (Latham, 2020; Sureda et al., 2016). HBOT has also been 
shown to modulate the inflammatory process through the production of reactive oxygen species 
(ROS) (Kocaman, 2020; Sureda et al., 2016). In large amounts, ROS production is detrimental 
for cells; however, a moderate increase can be beneficial since they act as cellular messengers in 
many signal transduction pathways. In this case, vascular endothelial growth factor (VEGF) and 
endothelial-1, key promoters of the angiogenic process and myofibroblast differentiation, are 
upregulated via ROS production which in turn advances chronic wound healing (Thom, 2009; 
Sureda et al., 2016). In a study performed by Nguyen et al. on diabetic mice, treatment with 
hyperbaric oxygen was shown to increase ROS and accelerate wound healing compared to 
untreated mice, with more completed and extended reepithelization (2020). 




 The prevalence of age-related disorders is on the rise as a result of the increase in life 
expectancy. For example, Alzheimer’s Disease (AD) is the most common cause of dementia in 
older adults and is ranked as the sixth leading cause of death in the United States. Despite its 
predominance, however, there is presently no cure for this disease and no effective treatment to 
slow progression (Shapira et al., 2018; Louisiana State University, 2019). HBOT is currently 
being examined as an alternative treatment for AD, as it has been shown to improve neurological 
functions and life quality in other similar incidents such as stroke and traumatic brain injury. AD 
is characterized by senile plaques formed by deposits of beta-amyloid and neurofibrillary 
tangles, which ultimately lead to loss of synapses and degeneration of neurons (Shapira et al., 
2018). Recent evidence suggests that hypoxia in the brain tissue plays a major role in AD 
pathogenesis as a result of reduced cerebral perfusion pressure that promotes the acceleration of 
beta-amyloid deposition. As a result, hyperoxic conditions have the potential to increase cerebral 
perfusion, slow beta-amyloid deposition, and boost brain function (Louisiana State University, 
2019). In 2019, Harch et al. demonstrated the largest improvement in brain metabolism of any 
therapy for Alzheimer’s disease through the use of HBOT. After undergoing 40 HBOT 
treatments, the patient reported increased memory and concentration, sleep, conversation, 
appetite, resolved anxiety, and decreased disorientation (Harch et al., 2019). 
Gastrointestinal Diseases 
 Ulcerative colitis (UC) and Chron’s disease (CD) are characterized by chronic mucosal 
ulcers and increased frequency of bowel movements, often accompanied with lower 
gastrointestinal bleeding (Latham, 2020). Treatment options for these patients are limited and 
often invasive (Landsdorp et al., 2020). As a result of chronic inflammation, mucosal hypoxia 
results, therefore, HBOT has been hypothesized as an alternative treatment option. Previous 
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studies demonstrated the effectiveness of HBOT in a model of experimental colitis by decreasing 
tissue damage. Although its mechanism of action is not totally clear, expression levels of 
inflammatory mediators in the damaged tissue as well as neutrophil infiltration was reduced by 
HBOT (Parra et al., 2020). More studies are needed to confirm the optimal number of HBOT 
sessions for UC and CD patients. 
COVID-19 
The current COVID-19 pandemic has become an unprecedented event for healthcare 
systems worldwide, with a dramatic loss of human life that continues to grow each day despite 
the technological advancements that have led to a vaccine. The infectious disease is caused by 
SARS-CoV-2, which causes damage to tissues and organs of the infected host by direct infection 
of target cells or indirectly by prolonged activation of host defense responses (De Maio & 
Hightower, 2020). Symptoms presented by an infected person can range from asymptomatic to 
respiratory illness and death (Latham, 2020). Morbidity and mortality from this condition are due 
to the incidence of Acute Respiratory Distress Syndrome (ARDS) which is characterized by low 
arterial oxygen concentration and is likely the product of inflammation mounted by the patient’s 
own response to the infection (De Maio & Hightower, 2020). Dr. Richard Levitan recently made 
the striking observation that oxygen saturation levels fall to below 50% in the initial stage of 
COVID-19 before the onset of respiratory symptoms. This initial stage is now being understood 
as “silent hypoxia” (Levitan, 2020). This discovery may be critical in preventing respiratory 
failure, and HBOT has the potential to facilitate this as soon as a reduction of arterial oxygen 
concentration is detected. Currently, a COVID-19 multicenter trial is taking place to investigate 
the effects of HBOT on infected patients admitted to the hospital requiring oxygen (Latham, 
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2020). Hopefully, HBOT can be verified as a legitimate treatment for COVID-19 and can help to 
reduce the number of lives lost as a result of the pandemic. 
RISKS AND LIMITATIONS 
 As with any medical therapy, treatment brings both risks and benefits. The oxidative 
stress that occurs as a result of high concentrations of oxygen may cause cell and tissue damage 
including harm to DNA. If not adequately repaired, this can lead to mutations and therefore has 
the potential to initiate cancer (Speit et al., 2002). Despite this concern, however, a review of the 
scientific literature showed that the vast majority of published studies failed to demonstrate such 
an effect (Feldmeier et al., 1994). Patients may experience mild-to-severe pain from rupture of 
the middle ear, cranial sinuses, and (in rare cases) the teeth or lungs as a result of rapid pressure 
changes (Tibbles & Edelsburg, 1996). This can be avoided by teaching the patient mitigation 
strategies such as the auto inflation technique (Latham, 2020). Some limitations of HBOT exist 
in the United States despite the growing list of diseases and syndromes that it can treat. In 
relation to cost, HBOT is rather expensive, with an average 90-minute session costing between 
$300 and $400. The cost of 30-40 sessions can therefore range from $9,000 to $16,000. An 
economic analysis of hyperbaric-oxygen therapy in patients with osteoradionecrosis, however, 
reported a savings of $96,000 as compared with in-hospital, nonhyperbaric-oxygen therapy 
(Tibbles & Edelsburg, 1996). Next, a limited number of technical staff available makes the 
installation of hyperbaric chambers difficult, as this is a heavily regulated process in the US that 
requires strict adherence to manufacturer specifications (Howell, 2018). Finally, the number of 
medical schools who teach hyperbaric medicine is slim. The Undersea & Hyperbaric Medical 
Society (UHMS) offers fellowships at several universities for hyperbaric preventative and 




 Hyperbaric Oxygen Therapy is a branch of science that has many indications for 
treatment due to its ability to counter oxygen deficits, promote healing and angiogenesis, fight 
infection, and control inflammation. HBOT has been described as a “therapy in search of 
diseases” (Tibbles & Edelsburg, 1996) since it is open to development and progress given the 
wide range of diseases that it has been explored to treat. Evidence for its use in decompression 
illness, carbon monoxide poisoning, and chronic wounds is strong, but more research is needed 
for its use in Alzheimer’s disease, GI diseases, and COVID-19. Although there are risks 
associated with HBOT, it is accepted as a safe procedure when administered properly. Overall, 
Hyperbaric Oxygen Therapy is a relatively new treatment for the standards of contemporary 
medicine. As medical technology has matured, it is the proper time to complete clarification on 
the potential uses of HBOT. Supported research, advanced technological equipment, and funding 
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